The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Candesartan Hydrochlorothiazide 16 mg/12.5 mg Tablets

16/12.5 milligram(s) Tablet

Accord Healthcare Ireland Ltd.PA2315/151/001

Main Information

Trade NameCandesartan Hydrochlorothiazide 16 mg/12.5 mg Tablets
Active SubstancesCandesartan cilexetil
Strength16/12.5 milligram(s)
Dosage FormTablet
Licence HolderAccord Healthcare Ireland Ltd.
Licence NumberPA2315/151/001

Group Information

ATC CodeC09DA Angiotensin II antagonists and diuretics
C09DA06 candesartan and diuretics


Licence Issued20/04/2012
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available

Generics Information

Interchangeable List CodeIC0029-036-002
Interchangeable List DocumentPDF of Interchangeable List
« Back